Added value of using gene expression signature test Mammaprint for adjuvant chemotherapy decision-making in early breast cancer

Home  /  National Uptake and Case Studies  /  Added value of using gene expression signature test Mammaprint for adjuvant chemotherapy decision-making in early breast cancer
CountryAgencyYear work was carried outLinkDetails of use
AustriaGOEG2018National adaptation. Made no changes to the EUnetHTA report, added a German summary.
AustriaLBI-HTA2018http://eprints.hta.lbg.ac.at/1147/1/HTA-Projektbericht_Nr.102.pdfDissemination to decision makers.
BelgiumKCE2018https://kce.fgov.be/en/mammaprint%C2%AE-test-for-personalised-management-of-adjuvant-chemotherapy-decisions-in-early-breast National adaptation. Added local information.
ItalyAGENAS2018National adaptation. Added local information.
ItalyASSR REROngoingDissemination of the EUnetHTA report will be carried out through our website: news of publication and link; summary and results provided.
NetherlandsZINOngoingNational adaptation. Added local information.
NorwayNIPHNOOngoingNational adaptation.
SlovakiaUNIBA2018National adaptation. Added local information.
SpainAQUASOngoingThe OTCA04 assessment will be disseminated to Catalan regional decision makers (physicians societies, director of corresponding plan, and Health Services Planners).
SpainOSTEBA2018The OTCA04 assessment was disseminated among the coordinators of the Breast Cancer Screening Program, among gynaecologists and among relevant decision makers.
UKNICE2018https://www.evidence.nhs.uk/search?q=EUnetHTA

This was originally assessed in DG10 https://www.nice.org.uk/guidance/dg10 It is currently being updated as part of guidance on a broader topic area. The HTA to inform the update was published before the EUnetHTA assessment was available. EUnetHTA reports are indexed in NHS evidence a database managed by NICE that supports evidence.
CroatiaAAZOngoingDissemination - prepared the Summary and assessment elements B0001 and A0020 in Croatian (will be published on the AAZ website along with links to the full EUnetHTA assessment).
FranceHAS2019https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite-clinique-des-signatures-genomiques-dans-le-cancer-du-sein-de-stade-precoce-rapport-d-evaluation National adaptation. Added local information.